Andrew E. Van Ostrand

Andrew supports and advises a range of payer, medical device, life sciences, and association clients with research and analysis focused on healthcare policy and payment reform.

He applies his background in health technology, health insurance, and the medical device space to inform policy and advocacy as well as market strategy.

Andrew joined Avalere with 20 years of diverse healthcare experience. Prior to Avalere, he held a variety of leadership positions, including senior public policy, enterprise strategy, and market development roles at The Advisory Board Company (now part of United Healthcare), the Health Industry Distributors Association, Medtronic, and Cigna. Most recently he led government affairs and strategic partnerships at PatientPing, a Series C venture capital-backed health technology company. Andrew spent nearly 10 years as a registered federal and state lobbyist.

Andrew has a BA in political science from Northeastern University and a MSc in economics from Trinity College Dublin.

Authored Content

Tune into another episode of Avalere Health Essential Voice in our Start Your Day with Avalere series. In this segment, our policy experts discuss the topic of healthcare price transparency in terms of policy, compliance, and the potential impact of making previously confidential pricing information public.

The convergence of the seasonal influenza and the current COVID-19 vaccines will merge several distribution considerations for a diverse group of stakeholders.